Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01353625
Title Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU

Facility Status City State Zip Country Details
Cedars-Sinai Medical Center Los Angeles California 90048 United States Details
UCLA Los Angeles California 90095 United States Details
University of California, San Francisco Comprehensive Cancer Center and Cancer Research Institiute San Francisco California 94115 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109 United States Details
Henry Ford Medical Center - New Center One Detroit Michigan 48202 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10021 United States Details
Sarah Cannon Research Institute Drug Development Unit Nashville Tennessee 37203 United States Details
Mary Crowley Medical Research Center Dallas Texas 75201 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77303 United States Details
Gustave Roussy Villejuif Cedex 94805 France Details
Uniklinik Koln Koeln 50937 Germany Details
Universitatsklinikum Wurzburg Würzburg 97070 Germany Details
Hospital Val d'Hebron Barcelona 08035 Spain Details
Hospital Universitario Madrid Sanchinarro Madrid 28050 Spain Details
Hospital de Donosti San Sebastián (Guipuzcoa) 20014 Spain Details
Hospital Virgen del Rocio Sevilla 41013 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field